BASE life science successfully implements Veeva Vault CRM and Vault Medical for Italfarmaco’s Rare Disease Division
News
Copenhagen, March 5th, 2025 – BASE life science a leader in CRM implementation for the life sciences industry, is pleased to announce the successful completion of a Veeva Vault-based CRM system and Vault Medical platform for Italfarmaco’s Rare Disease division in Europe. The project, which was completed with remarkable efficiency, further strengthens Italfarmaco’s commitment to advancing treatments for rare diseases, including Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS).
The new CRM and Medical systems will streamline operations and support Italfarmaco’s mission to improve the lives of individuals living with a rare disease by enhancing communication, collaboration, and data management across teams.
“We are extremely pleased with how seamlessly the implementation was carried out by BASE life science. The team demonstrated exceptional knowledge of the pharma processes and a strong commitment to delivering the project on time.”
Alessandro Marcuzzi – Vice President, Rare Diseases Europe at Italfarmaco Group
A partnership built on expertise
BASE life science is proud to have contributed to Italfarmaco’s success by providing a dedicated team of skilled professionals.
“We are pleased to have partnered with Italfarmaco on such an impactful project,” said Dario Lorizzo, Client Director at BASE life science. “Italfarmaco’s work in rare diseases is critical, and we’re proud to have supported their efforts with a technology solution that enhances their ability to serve patients. The successful implementation of these two additional Vault systems reflects our commitment to delivering high-quality solutions that meet our clients’ needs while minimizing operational disruption.”
About Italfarmaco
Founded in 1938 in Milan, Italy, Italfarmaco is a private global pharmaceutical company that has led the successful development and approval of many pharmaceutical products around the world. The Italfarmaco group has operations in more than 90 countries through directly controlled or affiliated companies. The company is a leader in pharmaceutical research, product development, production, and commercialisation with proven success in many therapeutic areas including immuno-oncology, gynaecology, neurology, cardiovascular disease, and rare diseases. Italfarmaco’s rare disease unit includes programmes in Duchenne muscular dystrophy, Becker muscular dystrophy, amyotrophic lateral sclerosis, and polycythaemia vera.
Visit ItalfarmacoAbout BASE life science
BASE life science is an innovative and forward-thinking multinational, technology, product, and service consultancy headquartered in Copenhagen, Denmark specialised in creating business value from digital platforms and data. Their experienced teams optimise technology and business processes within the life sciences industry.
Powered by their dedicated teams’ hard work and efforts, BASE life science has been cemented as a reliable advisor in the life sciences industry, striving for continuous excellence to remain an entrusted partner that can bring their customers visions successfully to life.
BASE life science was recently acquired by Infosys, the global leader in next-generation digital services and consulting with over 345k employees in more than 50 countries and a global revenue of 17.53 billion dollars. With four decades of experience and the latest technologies at their service, they empower clients to navigate the digital transformation.
